11,287 Abbott Laboratories $ABT Shares Bought by Phoenix Financial Ltd.

Phoenix Financial Ltd. lifted its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 57.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 30,861 shares of the healthcare product maker’s stock after purchasing an additional 11,287 shares during the quarter. Phoenix Financial Ltd.’s holdings in Abbott Laboratories were worth $3,050,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ABT. Dogwood Wealth Management LLC increased its position in Abbott Laboratories by 15.4% during the third quarter. Dogwood Wealth Management LLC now owns 705 shares of the healthcare product maker’s stock worth $70,000 after buying an additional 94 shares during the last quarter. Elwood & Goetz Wealth Advisory Group LLC raised its holdings in Abbott Laboratories by 3.1% during the third quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 3,216 shares of the healthcare product maker’s stock valued at $318,000 after buying an additional 97 shares in the last quarter. Parkway Wealth Management Group LLC lifted its position in shares of Abbott Laboratories by 3.2% in the third quarter. Parkway Wealth Management Group LLC now owns 3,208 shares of the healthcare product maker’s stock worth $317,000 after buying an additional 98 shares during the last quarter. Signature Equity Partners LLC lifted its position in shares of Abbott Laboratories by 7.9% in the third quarter. Signature Equity Partners LLC now owns 1,363 shares of the healthcare product maker’s stock worth $135,000 after buying an additional 100 shares during the last quarter. Finally, St. Johns Investment Management Company LLC lifted its position in shares of Abbott Laboratories by 1.0% in the second quarter. St. Johns Investment Management Company LLC now owns 9,859 shares of the healthcare product maker’s stock worth $895,000 after buying an additional 101 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Wells Fargo & Company increased their price objective on Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a report on Thursday, October 22nd. BTIG Research reduced their target price on Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating for the company in a report on Thursday, October 22nd. Argus lowered Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, October 27th. UBS Group decreased their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Finally, Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target on the stock in a report on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $118.32.

View Our Latest Research Report on ABT

Abbott Laboratories Trading Up 0.1%

Shares of NYSE:ABT opened at $108.59 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.00 and a current ratio of 1.45. The stock’s 50-day moving average is $103.93 and its 200-day moving average is $101.74. The company has a market cap of $188.08 billion, a P/E ratio of 40.52, a P/E/G ratio of 1.90 and a beta of 0.54. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $132.02.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting the consensus estimate of $1.42. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The business had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. During the same quarter in the previous year, the firm earned $1.30 EPS. The firm’s revenue was up 14.5% compared to the same quarter last year. Equities research analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s payout ratio is currently 94.03%.

Insider Buying and Selling

In other news, EVP Mary Moreland sold 3,500 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total transaction of $406,000.00. Following the completion of the transaction, the executive vice president directly owned 100,791 shares in the company, valued at $11,691,756. The trade was a 3.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Featured Articles

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.